Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy |
| |
| Institution: | 1. Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610 Antwerpen, Belgium;2. National Institute of Hygiene and Epidemiology, Yersin Street 1, Hanoi 10000, Vietnam;3. National Reference Centre Bordetella, Service Immunology, Scientific Institute of Public Health (WIV-ISP), 1180 Brussels, Belgium;4. Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Belguim;5. Centre for Health Economics Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerpen, Belgium;6. School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam;1. Centre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208, Ouagadougou 01, Burkina Faso;2. Service de Parasitologie, Université Cheikh Anta Diop (UCAD), BP 5005 UCAD, Dakar, Senegal;3. Kenya Medical Research Institute, Centre for Geographic Medicine Research Coast (KEMRI-CGMRC), P.O. Box 230, Kilifi 80108, Kenya;4. Nuffield Department of Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom;1. Centre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208, Ouagadougou 01, Burkina Faso;2. Service de Parasitologie, Université Cheikh Anta Diop (UCAD), BP 5005 UCAD, Dakar, Senegal;1. Center for Infectious Disease Control, National Institute of Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands;2. Emory University, Rollins School of Public Health, Grace Crum Rollins Building, 1518 Clifton Road, Atlanta, GA 30322, USA;3. Laboratorium voor Infectieziekten, Van Swietenlaan 2, 9728 NZ Groningen, The Netherlands;4. Groene Hart Ziekenhuis, Graaf Florisweg 77-79, 2805 AH Gouda, The Netherlands;1. HealthPartners Institute for Education and Research, Minneapolis, MN, United States;2. Yale University School of Medicine, Department of Obstetrics, Gynecology, & Reproductive Sciences, New Haven, CT, United States;3. Kaiser Permanente of Northern California, Oakland, CA, United States;4. Kaiser Permanente of Southern California, Pasadena, CA, United States;5. Kaiser Permanente Northwest, Portland, OR, United States;6. Harvard Pilgrim Health Care Institute & Harvard Medical School, Boston, MA, United States;7. Institute for Health Research, Kaiser Permanente Colorado and Department of Ambulatory Care Services, Denver Health, Denver, CO, United States;8. Group Health Cooperative, Seattle, WA, United States;9. Kaiser Permanente Georgia, Atlanta, GA, United States;10. Centers for Disease Control and Prevention, Atlanta, GA, United States;1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, MS D26, Atlanta, GA 30333, USA;2. Birth Defects Branch, Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities (NCBDDD), CDC, Atlanta, GA 30333, USA;3. Women''s Health and Fertility Branch, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, Atlanta, GA 30333, USA;4. Community Interventions for Infection Control Unit, Division of Global Migration and Quarantine, CDC, Atlanta, GA 30333, USA;1. Department of Pediatrics, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel;2. The Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Efron St. 1, Haifa 31096, Israel;3. Clinical Microbiology Laboratory, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel;4. Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Golomb St. 47, Haifa 31048, Israel;1. Department of Obstetrics and Gynecology, Monash University, Melbourne, Australia;2. Ritchie Center, Hudson Institute of Medical Research, Melbourne, Australia;3. Monash Health, Melbourne, Australia |
| |
| Abstract: | A pertussis vaccination during pregnancy has recently been adopted in several countries to indirectly protect young infants. This study assessed the effect of adding a pertussis component to the tetanus vaccination, in the pregnancy immunization program in Vietnam.A randomized controlled trial was performed. Pregnant women received either a Tdap (tetanus, diphtheria acellular pertussis) vaccine or a tetanus only vaccine between 19 and 35 weeks’ gestational age. Immunoglobulin G (IgG) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous hemaglutinin (FHA) and pertactin (Prn) were measured using commercial ELISA tests, at baseline, 1 month after maternal vaccination, at delivery, and in infants from cord blood and before and after the primary series (EPI: month 2-3-4) of a pertussis containing vaccine.Significantly higher geometric mean concentrations (GMC) were observed for all 3 measured pertussis antigens in the offspring of the Tdap group, up to 2 months of age. One month after completion of the primary infant vaccination schedule, anti-Prn GMC, but not anti-PT and anti-FHA GMCs, was significantly (p = 0.006) higher in the control group.Maternal antibodies induced by vaccination during pregnancy close the susceptibility gap for pertussis in young infants. Limited interference with the infant vaccine responses was observed. Whether this interference effect disappears with the administration of a fourth vaccine dose is further studied. |
| |
| Keywords: | Pertussis Vaccination Pregnancy Maternal antibodies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
